Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Medical Science (TMIMS), today announce their ...

AGC Biologics, your friendly CDMO expert, announced an agreement to provide comprehensive development and manufacturing for Rarity PBC's gene therapy.

Syngene International plans to add bioconjugation suite for end-to-end ADC development: Our Bureau, Bengaluru Thursday, October 23, 2025, 15:15 Hrs [IST] Syngene International, a ...

Microbial systems offer distinct advantages in protein expression, saving costs and time, and offering well-characterized host genetics and ease of scale-up. 2 However, challenges remain in process ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and formulation capabilities with the launch of a GMP-like mRNA manufacturing service, ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

Syngene expands its Biologics facility in Bengaluru, adding ADC bioconjugation to accelerate development timelines and enhance services.

Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in Paris, a prestigious hub for leading cell therapy research, Astraveus is committed to revolutionizing the development and ...

The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...

In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to GMP with greater speed and efficiency. This webinar will highlight ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...